New short-term-helpful ovarian cancer drug, $14k/m
Post# of 72447
(Total Views: 160)
Posted On: 03/28/2017 7:05:46 PM
New short-term-helpful ovarian cancer drug, $14k/month for new drug from TSRO.
Progression-free survival is 9 months, as opposed to 4 months without treatment.
Serious side effects, too. Kevetrin is desperately needed, sure hope it works.
Progression-free survival is 9 months, as opposed to 4 months without treatment.
Serious side effects, too. Kevetrin is desperately needed, sure hope it works.
Quote:
Zejula may cause serious side effects including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with Zejula. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop your treatment.
Symptoms of low blood cell counts (low red blood cells, low white blood cells, and low platelets) are common during treatment, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include:
weakness
feeling tired
weight loss
frequent infections
fever
shortness of breath
blood in urine or stool
bruising or bleeding more easily
(0)
(0)